In the last trading session, 7.11 million Sutro Biopharma Inc (NASDAQ:STRO) shares changed hands as the company’s beta touched 1.64. With the company’s per share price at $0.93 changed hands at $0.12 or 15.10% during last session, the market valuation stood at $78.12M. STRO’s last price was a discount, traded about -559.14% off its 52-week high of $6.13. The share price had its 52-week low at $0.81, which suggests the last value was 12.9% up since then. When we look at Sutro Biopharma Inc’s average trading volume, we note the 10-day average is 3.08 million shares, with the 3-month average coming to 1.22 million.
Analysts gave the Sutro Biopharma Inc (STRO) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.36. If we narrow down to specifics, the data shows that 0 out of 5 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended STRO as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Sutro Biopharma Inc’s EPS for the current quarter is expected to be 0.
Sutro Biopharma Inc (NASDAQ:STRO) trade information
Instantly STRO was in green as seen at the end of in last trading. With action -30.93%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -49.33%, with the 5-day performance at -30.93% in the red. However, in the 30-day time frame, Sutro Biopharma Inc (NASDAQ:STRO) is -46.41% down. Looking at the short shares, we see there were 4.46 million shares sold at short interest cover period of 4.9 days.
The consensus price target for the stock as assigned by Wall Street analysts is 12, meaning bulls need an upside of 92.25% from its current market value. According to analyst projections, STRO’s forecast low is 12 with 12 as the target high. To hit the forecast high, the stock’s price needs a -1190.32% plunge from its current level, while the stock would need to soar -1190.32% for it to hit the projected low.
Sutro Biopharma Inc (STRO) estimates and forecasts
Year-over-year growth is forecast to reach -24.03% down from the last financial year.
Consensus estimates given by 9 financial analysts project the company’s revenue in the current quarter to hit an average of 11.61M. 9 analysts are of the opinion that Sutro Biopharma Inc’s revenue for the current quarter will be 11.54M. The company’s revenue for the corresponding quarters a year ago was 13.01M and 25.71M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -10.77%. The estimates for the next quarter sales put growth at -55.10%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 21.96%. The 2025 estimates are for Sutro Biopharma Inc earnings to increase by 30.93%, but the outlook for the next 5-year period is at 32.32% per year.
STRO Dividends
Sutro Biopharma Inc is expected to release its next quarterly earnings report on 2025-Mar-12.
Sutro Biopharma Inc (NASDAQ:STRO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 4.21% of Sutro Biopharma Inc shares while 73.99% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 77.25%. There are 73.99% institutions holding the Sutro Biopharma Inc stock share, with SUVRETTA CAPITAL MANAGEMENT, LLC the top institutional holder. As of 2024-06-30, the company held 9.4906% of the shares, roughly 7.71 million STRO shares worth $22.59 million.
BLACKROCK INC. holds the second largest percentage of outstanding shares, with 8.5082% or 6.91 million shares worth $20.25 million as of 2024-06-30.
Among Mutual Funds, the top two as of Dec 31, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF . With 2.42 shares estimated at $2.25 million under it, the former controlled 2.93% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.66% of the shares, roughly 2.2 shares worth around $2.05 million.
